AI Article Synopsis
- Acute rejection is the main concern after intestinal transplants, but new immunosuppressive drugs have decreased severe cases.
- According to data from the International Intestinal Transplant Registry, anti-IL-2 antibodies show some benefits over antilymphocyte treatments for long-term survival, though results may vary based on dosage and timing.
- The key distinction is that anti-IL-2 antibodies suppress CD4+ CD25+ T lymphocytes, which are crucial for tolerance, suggesting future protocols might eliminate anti-IL-2 antibodies to promote tolerance.
Article Abstract
Acute rejection remains the main risk factor following intestinal transplantation. New immunosuppressive agents have substantially reduced the incidence of severe acute rejection. The question arises, which is the most powerful immunosuppressive combination with the lowest incidence of side effects? According to International Intestinal Transplant Registry data, anti-IL-2 antibodies are slightly advantageous compared with antilymphocyte preparations with respect to long-term patient survival. However, different antilymphocyte preparations are used in different doses and at different time points. The anti-IL-2 antibodies daclizumab and basiliximab were also used in different protocols. Therefore, final results on efficacy are awaited. The most important difference between IL-2 antibodies and antilymphocyte preparations is the suppression of CD4+ CD25+ T lymphocytes by anti-IL-2 antibodies. Antilymphocyte preparations do not affect CD4+ CD25+ T cells. Because regulatory CD4+ CD25+ T cells are essential for tolerance induction, protocols attempting tolerance may omit anti-IL-2 antibodies in the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.transproceed.2005.03.131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes.
J Neuroinflammation
December 2024
Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Background: The global incidence of type 2 diabetes (T2D) is rapidly increasing, with retinopathy being its most common complication and a leading cause of preventable blindness. Although the precise mechanisms involved in the development of diabetic retinopathy (DR) are not fully understood, defective immunomodulation is a recognized key factor in its pathophysiology. Regulatory T cells (Treg) regulate inflammation and promote regeneration, and while they are known to have important anti-inflammatory and neuroprotective roles in other tissues, including central nervous system, their role in the diabetic retina remains largely unknown.
View Article and Find Full Text PDFAn antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: Potent anti-tumor activity and reduced systemic toxicity in mice.
Eur J Pharmacol
January 2025
School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang, Liaoning, 110016, China; Shenyang Sunshine Pharmaceuticals Co., Ltd, Economic and Technological Development Zone, Shenyang, Liaoning, 110027, China.
The anti-tumor efficacy of immune checkpoint inhibitors can be enhanced by combining them with interleukin-2 (IL-2), which promotes the clonal expansion of antigen-activated CD8 T cells and natural killer cells. However, IL-2 can simultaneously bind to endothelial cells and regulatory T cells to induce adverse and immunosuppressive effects. Such off-target binding can be inhibited by co-administering IL-2 with anti-IL-2 antibodies, but these antibodies can interact with neonatal Fc receptor to protect the IL-2 from lysosomal degradation, leading to substantial toxicity.
View Article and Find Full Text PDFIL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines.
Proc Natl Acad Sci U S A
November 2024
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.
One driver of the high failure rates of clinical trials for therapeutic cancer vaccines is likely the inability to sufficiently engage conventional dendritic cells (cDCs), the antigen-presenting cell (APC) subset that is specialized in priming antitumor T cells. Here, we demonstrate that, relative to vaccination with an injectable mesoporous silica rod (MPS) vaccine alone (Vax), combining MPS vaccines with CD122-biased IL-2/anti-IL-2 antibody complexes (IL-2cx) drives ~3-fold expansion of cDCs at the vaccination sites, vaccine-draining lymph nodes, and spleens of treated mice. Furthermore, relative to Vax alone, Vax+IL-2cx led to a ~3-fold increase in the numbers of CD8 T cells and ~15-fold increase in the numbers of NK cells at the vaccination site.
View Article and Find Full Text PDFWiskott-Aldrich syndrome protein maintains regulatory T cell tolerance by modulating their surface IL-2 receptor levels.
J Autoimmun
December 2024
National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China; Division of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. Electronic address:
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency condition caused by ablation of functional WAS protein (WASP) expression, and associated with susceptibility to infections, eczema, and autoimmunity. Regulatory T cell (Treg) defects are an important cause of autoimmunity in WAS. Currently, the mechanisms underlying cytoskeleton involvement in Treg-regulated autoimmunity remain unclear, and WAS is an excellent model for investigation of this question.
View Article and Find Full Text PDFProductions of Th2 cytokines, IL-4 and IL-10, were enhanced via the function of IL-2 from anti-CD3 antibody-stimulated mouse spleen cells treated with caffeic acid phenethyl ester.
J Oral Biosci
December 2024
Chemistry Laboratory, Asahi University School of Dentistry, Mizuho, Gifu, 501-0296, Japan. Electronic address:
Objectives: Interleukin (IL)-2 production by mouse spleen cells stimulated with an anti-CD3 antibody is significantly enhanced by caffeic acid phenethyl ester (CAPE), a major constituent of Chinese propolis (CP). In this study, we evaluated the functional significance of IL-2 in CAPE-treated activated spleen cells.
Methods: Mouse spleen cells were stimulated with an anti-CD3 monoclonal antibody in the presence of CAPE.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!